Skin Diseases, Infectious
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings revealed that pvl-positive MRSA associated with deep-seated skin infections are spreading in Japanese communities, particularly in Ishigaki, Okinawa.
|
28552322 |
2017 |
Skin Diseases, Infectious
|
0.100 |
Biomarker
|
group |
BEFREE |
In an area where PVL-containing MRSA is prevalent, skin infection risk was increased among MRSA nasal carriers compared with methicillin-susceptible S. aureus carriers and noncarriers, but risk differential diminished over time.
|
20409369 |
2010 |
Skin Diseases, Infectious
|
0.100 |
Biomarker
|
group |
BEFREE |
Topical retapamulin (Altabax, Altargo) is the first pleuromutilin antibacterial approved for the treatment of uncomplicated superficial skin infections caused by Staphylococcus aureus (excluding methicillin-resistant S. aureus [MRSA]) and Streptococcus pyogenes in patients aged > or = 9 months.
|
18973410 |
2008 |
Skin Diseases, Infectious
|
0.100 |
Biomarker
|
group |
BEFREE |
Community-based intervention to manage an outbreak of MRSA skin infections in a county jail.
|
20466702 |
2010 |
Skin Diseases, Infectious
|
0.100 |
Biomarker
|
group |
BEFREE |
An in vivo BALB/c mice, skin infection models revealed that treatment with VM-loaded polymersomes significantly reduced the MRSA burden compared with plain VM and blank polymersomes.
|
27890573 |
2017 |
Skin Diseases, Infectious
|
0.100 |
Biomarker
|
group |
BEFREE |
CA-MRSA strains most commonly cause skin infections, but may lead to more severe diseases, and consequently the patient's death.
|
20544179 |
2010 |
Skin Diseases, Infectious
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, PLNA34 showed high levels of protection in the CA-MRSA mouse skin infection model.
|
27718524 |
2017 |
Skin Diseases, Infectious
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results showed that PVL was strongly associated with pyomyositis and osteomyelitis, and that there is a high prevalence of PVL-MRSA skin infections in Benin.
|
23924370 |
2013 |
Skin Diseases, Infectious
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Eradication treatment of MRSA spa types causing more skin infections may be warranted.
|
23922169 |
2014 |
Skin Diseases, Infectious
|
0.100 |
Biomarker
|
group |
BEFREE |
We report the first complete genome sequence of an ST93-MRSA-IV clinical isolate that caused severe invasive infection and a familial outbreak of skin infection.
|
20729356 |
2010 |
Skin Diseases, Infectious
|
0.100 |
Biomarker
|
group |
BEFREE |
Identifying CA-MRSA virulence determinants and the concerted regulation of these factors will foster development of vaccines and therapeutics designed to control CA-MRSA skin infections.
|
18317037 |
2008 |
Skin Diseases, Infectious
|
0.100 |
Biomarker
|
group |
BEFREE |
We conducted S. aureus surveillance in the outbreak region and a case-control study in 1 community, comparing 34 case patients with MRSA skin infection with 94 control subjects.
|
15116291 |
2004 |
Skin Diseases, Infectious
|
0.100 |
Biomarker
|
group |
BEFREE |
Coupled to a low cytotoxic activity, we believe our lead compound can be developed into a topical antibacterial agent to replace mupirocin as the first-line drug for treating MRSA skin infections.
|
30103288 |
2019 |
Skin Diseases, Infectious
|
0.100 |
Biomarker
|
group |
BEFREE |
Pulsed-field type USA300 were MRSA, PVL-positive, unencapsulated strains that were associated with deep skin infections and recurrent disease.
|
21631600 |
2011 |